Journal Watch · Annals of Internal Medicine · 2026

Comparative Effectiveness and Harm of Seasonal Influenza Vaccines in Adults Who Are Not Pregnant or Immunocompromised: A Rapid Review for the American College of Physicians.

(PROSPERO: CRD420251114496).

Dobrescu AI, Sharifan A, Sommer I et al.Annals of Internal Medicine4 min readPharma relevance 95/100

DOI: 10.7326/annals-25-04028PMID: 41248500Study type: randomised / controlled clinical trial

TL;DR

(PROSPERO: CRD420251114496).

Key findings

  • Evidence was lacking for several comparisons and outcomes.
  • Broad definitions of serious adverse events may have inflated risk estimates.<h4>Conclusion</h4>High-dose and recombinant vaccines improve protection compared with standard vaccines, but high-dose vaccines increase fever risk.
  • Evidence for mRNA vaccines is limited and should be cautiously interpreted.<h4>Primary funding source</h4>American College of Physicians.
  • (PROSPERO: CRD420251114496).

What they did

High-dose vaccines probably caused fewer serious adverse events in all adults and those aged 65 years or older (moderate CoE). Recombinant vaccines reduced laboratory-confirmed influenza in all adults and those younger than 65 years compared with standard vaccines (high CoE). Evidence from 2 RCTs indicated that mRNA vaccines may increase serious adverse events in all adults and those younger than 65 years compared with standard vaccines (low CoE).<h4>Limitations</h4>RCTs evaluating laboratory-confirmed influenza and influenza-related hospitalization or death are limited.

Full abstract (original)

Background: <h4>Background</h4>Seasonal influenza is a contagious viral respiratory illness that causes yearly epidemics.<h4>Purpose</h4>To assess the comparative effectiveness and harm of standard and newer and enhanced influenza vaccines in nonpregnant, nonimmunocompromised adults.<h4>Data sources</h4>Medline and Embase between May 2023 and July 2025, and a systematic review by the European Centre for Disease Prevention and Control (ECDC) to identify studies published before May 2023.<h4>Study selection</h4>Two investigators independently selected English-language randomized controlled trials (RCTs) and nonrandomized studies of interventions (NRSIs).<h4>Data extraction</h4>For newly included studies, one reviewer extracted data and assessed certainty of evidence (CoE), which was verified by a second reviewer; 2 reviewers independently assessed risk of bias. For studies from the ECDC report, original data and risk-of-bias assessments were used.<h4>Data synthesis</h4>The review included 35 RCTs and 5 NRSIs. Compared with standard vaccines, high-dose vaccines reduced laboratory-confirmed influenza in adults aged 65 years or older (high CoE) but increased the risk for fever in this group (high CoE).

What they did: High-dose vaccines probably caused fewer serious adverse events in all adults and those aged 65 years or older (moderate CoE). Recombinant vaccines reduced laboratory-confirmed influenza in all adults and those younger than 65 years compared with standard vaccines (high CoE). Evidence from 2 RCTs indicated that mRNA vaccines may increase serious adverse events in all adults and those younger than 65 years compared with standard vaccines (low CoE).<h4>Limitations</h4>RCTs evaluating laboratory-confirmed influenza and influenza-related hospitalization or death are limited.

Results & conclusions: Evidence was lacking for several comparisons and outcomes. Broad definitions of serious adverse events may have inflated risk estimates.<h4>Conclusion</h4>High-dose and recombinant vaccines improve protection compared with standard vaccines, but high-dose vaccines increase fever risk. Evidence for mRNA vaccines is limited and should be cautiously interpreted.<h4>Primary funding source</h4>American College of Physicians. (PROSPERO: CRD420251114496).

Abstract © the authors / Annals of Internal Medicine (2026). Reproduced here for discussion and indexing, with attribution. Read the original at https://doi.org/10.7326/annals-25-04028 · PubMed 41248500.

Why it matters for pharma & biotech

  • Directly relevant to teams in mRNA / delivery technology, vaccines — the abstract reports new data in that space, so competitive and pipeline teams should read the full text.
  • Because it reports human data, it can inform indication, endpoint and comparator decisions faster than preclinical work.
  • For searchers: the full abstract is reproduced below, so you can judge relevance before opening the publisher page.

Modalities & themes detected: mRNA / delivery technology · vaccines

Limitations & what to check in the full text

  • This brief is based on the published abstract only. Effect sizes, subgroup results and safety detail in the full text may qualify the headline findings.
  • The abstract reports its conclusions qualitatively, without headline effect sizes — read the full text before citing a magnitude.

Frequently asked questions

What did this Annals of Internal Medicine study find?

(PROSPERO: CRD420251114496).

What type of study is this?

It is a randomised / controlled clinical trial, published in Annals of Internal Medicine in 2026. High-dose vaccines probably caused fewer serious adverse events in all adults and those aged 65 years or older (moderate CoE).

Where can I read the original paper?

The original is at the publisher via DOI 10.7326/annals-25-04028. PubMed ID: 41248500. BioStudioAI reproduces the abstract for discussion and links to the source.

How to cite the original: Dobrescu AI, Sharifan A, Sommer I et al.. Comparative Effectiveness and Harm of Seasonal Influenza Vaccines in Adults Who Are Not Pregnant or Immunocompromised: A Rapid Review for the American College of Physicians.. Annals of Internal Medicine (2026). DOI: 10.7326/annals-25-04028.
This brief: BioStudioAI Journal Watch, 29 October 2026. https://biostudioai.com/blog/papers/comparative-effectiveness-and-harm-of-seasonal-influenza-vaccines-in-adu-504028/

Reading papers is step one. Analysing the data is the work.

BioStudioAI turns raw lab files into QC'd results, statistics, figures, reports and slides — hosted on your servers, every number computed, nothing typed.

Open BioStudioAI More guides